• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Incorporating a β-hairpin sequence motif to increase intracellular stability of a peptide-based PROTAC.引入β-发夹序列基序以提高基于肽的PROTAC的细胞内稳定性。
Biochem Eng J. 2023 Oct;199. doi: 10.1016/j.bej.2023.109063. Epub 2023 Aug 9.
2
CPProtectides: Rapid uptake of well-folded β-hairpin peptides with enhanced resistance to intracellular degradation.CP保护剂:对细胞内降解具有增强抗性的折叠良好的β-发夹肽的快速摄取。
Pept Sci (Hoboken). 2019 Mar;111(2). doi: 10.1002/pep2.24092. Epub 2018 Sep 23.
3
Discovery of a Keap1-dependent peptide PROTAC to knockdown Tau by ubiquitination-proteasome degradation pathway.发现一种依赖Keap1的肽类PROTAC,通过泛素化-蛋白酶体降解途径敲低Tau蛋白。
Eur J Med Chem. 2018 Feb 25;146:251-259. doi: 10.1016/j.ejmech.2018.01.063. Epub 2018 Feb 4.
4
Expansion of targeted degradation by Gilteritinib-Warheaded PROTACs to ALK fusion proteins.吉特替尼弹头 PROTACs 通过靶向降解扩展到 ALK 融合蛋白。
Bioorg Chem. 2024 Apr;145:107204. doi: 10.1016/j.bioorg.2024.107204. Epub 2024 Feb 14.
5
Peptide-based PROTAC degrader of FOXM1 suppresses cancer and decreases GLUT1 and PD-L1 expression.基于肽的 FOXM1 PROTAC 降解剂抑制癌症并降低 GLUT1 和 PD-L1 的表达。
J Exp Clin Cancer Res. 2022 Sep 29;41(1):289. doi: 10.1186/s13046-022-02483-2.
6
PROTAC-DB 2.0: an updated database of PROTACs.PROTAC-DB 2.0:一个更新的 PROTAC 数据库。
Nucleic Acids Res. 2023 Jan 6;51(D1):D1367-D1372. doi: 10.1093/nar/gkac946.
7
Proteolysis-targeting chimeras (PROTACs) in cancer therapy.蛋白水解靶向嵌合体(PROTACs)在癌症治疗中的应用。
Mol Cancer. 2022 Apr 11;21(1):99. doi: 10.1186/s12943-021-01434-3.
8
Bridged Proteolysis Targeting Chimera (PROTAC) Enables Degradation of Undruggable Targets.桥连蛋白水解靶向嵌合体(PROTAC)能够降解不可成药的靶标。
J Am Chem Soc. 2022 Dec 14;144(49):22622-22632. doi: 10.1021/jacs.2c09255. Epub 2022 Nov 30.
9
Recent Advances in PROTACs for Drug Targeted Protein Research.蛋白水解靶向嵌合体(PROTACs)在药物靶向蛋白研究中的最新进展。
Int J Mol Sci. 2022 Sep 7;23(18):10328. doi: 10.3390/ijms231810328.
10
Systematic prediction of degrons and E3 ubiquitin ligase binding via deep learning.通过深度学习系统地预测降解信号和 E3 泛素连接酶结合。
BMC Biol. 2022 Jul 14;20(1):162. doi: 10.1186/s12915-022-01364-6.

引用本文的文献

1
Advances in KEAP1-based PROTACs as emerging therapeutic modalities: Structural basis and progress.基于KEAP1的PROTACs作为新兴治疗方式的进展:结构基础与研究进展
Redox Biol. 2025 Jul 21;85:103781. doi: 10.1016/j.redox.2025.103781.
2
The Peptide PROTAC Modality: A New Strategy for Drug Discovery.肽类PROTAC技术:药物发现的新策略。
MedComm (2020). 2025 Mar 24;6(4):e70133. doi: 10.1002/mco2.70133. eCollection 2025 Apr.
3
Tau degradation in Alzheimer's disease: Mechanisms and therapeutic opportunities.阿尔茨海默病中tau蛋白的降解:机制与治疗机遇
Alzheimers Dement. 2025 Mar;21(3):e70048. doi: 10.1002/alz.70048.
4
Effect of TIMPs and their minimally engineered variants in blocking invasion and migration of brain cancer cells.基质金属蛋白酶组织抑制因子(TIMPs)及其最小工程变体在阻断脑癌细胞侵袭和迁移中的作用。
Oncotarget. 2025 Feb 28;16:118-130. doi: 10.18632/oncotarget.28691.
5
Selection of Nucleotide-Encoded Mass Libraries of Macrocyclic Peptides for Inaccessible Drug Targets.用于不可接近药物靶点的大环肽核苷酸编码质量文库的选择。
Chem Rev. 2024 Nov 13;124(21):12213-12241. doi: 10.1021/acs.chemrev.4c00422. Epub 2024 Oct 25.

本文引用的文献

1
Cell-Permeable PROTAC Degraders against KEAP1 Efficiently Suppress Hepatic Stellate Cell Activation through the Antioxidant and Anti-Inflammatory Pathway.针对KEAP1的细胞渗透性PROTAC降解剂通过抗氧化和抗炎途径有效抑制肝星状细胞激活。
ACS Pharmacol Transl Sci. 2022 Dec 7;6(1):76-87. doi: 10.1021/acsptsci.2c00165. eCollection 2023 Jan 13.
2
PROTAC Degrader of Estrogen Receptor α Targeting DNA-Binding Domain in Breast Cancer.靶向乳腺癌雌激素受体α DNA结合结构域的PROTAC降解剂
ACS Pharmacol Transl Sci. 2022 Oct 12;5(11):1109-1118. doi: 10.1021/acsptsci.2c00109. eCollection 2022 Nov 11.
3
Proteolysis Targeting Chimeras (PROTACs): A Perspective on Integral Membrane Protein Degradation.蛋白酶靶向嵌合体(PROTACs):关于整合膜蛋白降解的观点
ACS Pharmacol Transl Sci. 2022 Sep 5;5(10):849-858. doi: 10.1021/acsptsci.2c00142. eCollection 2022 Oct 14.
4
Non-small molecule PROTACs (NSM-PROTACs): Protein degradation kaleidoscope.非小分子PROTAC(NSM-PROTAC):蛋白质降解万花筒
Acta Pharm Sin B. 2022 Jul;12(7):2990-3005. doi: 10.1016/j.apsb.2022.02.022. Epub 2022 Feb 26.
5
PROTACs: past, present and future.PROTACs:过去、现在和未来。
Chem Soc Rev. 2022 Jun 20;51(12):5214-5236. doi: 10.1039/d2cs00193d.
6
Circular dichroism for secondary structure determination of proteins with unfolded domains using a self-organising map algorithm SOMSpec.使用自组织映射算法SOMSpec通过圆二色性测定具有未折叠结构域的蛋白质的二级结构。
RSC Adv. 2021 Jul 7;11(39):23985-23991. doi: 10.1039/d1ra02898g. eCollection 2021 Jul 6.
7
How Cargo Identity Alters the Uptake of Cell-Penetrating Peptide (CPP)/Cargo Complexes: A Study on the Effect of Net Cargo Charge and Length.货物身份如何改变细胞穿透肽 (CPP)/货物复合物的摄取:净货物电荷和长度的影响研究。
Cells. 2022 Apr 1;11(7):1195. doi: 10.3390/cells11071195.
8
Kill Two Birds with One Stone: A Multifunctional Dual-Targeting Protein Drug to Overcome Imatinib Resistance in Philadelphia Chromosome-Positive Leukemia.一石二鸟:一种多功能双靶点蛋白药物,克服费城染色体阳性白血病的伊马替尼耐药性。
Adv Sci (Weinh). 2022 May;9(13):e2104850. doi: 10.1002/advs.202104850. Epub 2022 Mar 3.
9
Targeted β-catenin ubiquitination and degradation by multifunctional stapled peptides.多功能订书肽靶向 β-连环蛋白的泛素化和降解。
J Pept Sci. 2022 Jul;28(7):e3389. doi: 10.1002/psc.3389. Epub 2021 Dec 22.
10
An E3 ligase guide to the galaxy of small-molecule-induced protein degradation.一种 E3 连接酶引导的小分子诱导蛋白降解的星系。
Cell Chem Biol. 2021 Jul 15;28(7):1000-1013. doi: 10.1016/j.chembiol.2021.04.002. Epub 2021 Apr 22.

引入β-发夹序列基序以提高基于肽的PROTAC的细胞内稳定性。

Incorporating a β-hairpin sequence motif to increase intracellular stability of a peptide-based PROTAC.

作者信息

Hymel Hannah C, Anderson Jeffery C, Liu Dong, Gauthier Ted J, Melvin Adam T

机构信息

Cain Department of Chemical Engineering, Louisiana State University, Baton Rouge, LA, 70803.

LSU AgCenter Biotechnology Lab, Louisiana State University, Baton Rouge, LA 70803.

出版信息

Biochem Eng J. 2023 Oct;199. doi: 10.1016/j.bej.2023.109063. Epub 2023 Aug 9.

DOI:10.1016/j.bej.2023.109063
PMID:37637833
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10455042/
Abstract

Proteolysis targeting chimeras (PROTACs) have emerged as a new class of therapeutics that utilize the ubiquitin-proteasome system (UPS) to facilitate proteasomal degradation of "undruggable" targets. Peptide-based PROTACs contain three essential components: a binding motif for the target protein, a short amino acid sequence recognized by an E3 ligase called a degron, and a cell penetrating peptide to facilitate uptake into intact cells. While peptide-based PROTACs have been shown to successfully degrade numerous targets, they have often been found to exhibit low cell permeability and high protease susceptibility. Prior work identified peptides containing a β-hairpin sequence motif that function not only as protecting elements, but also as CPPs and degrons. The goal of this study was to investigate if a β-hairpin sequence could replace commonly used unstructured peptides sequences as the degron and the CPP needed for PROTAC uptake and function. The degradation of the protein Tau was selected as a model system as several published works have identified a Tau binding element that could easily be conjugated to the β-hairpin sequence. A series of time- and concentration-dependent studies confirmed that the βhairpin sequence was an adequate alternative CPP and degron to facilitate the proteasomemediated degradation of Tau. Microscopy studies confirmed the time-dependent uptake of the PROTAC and a degradation assay confirmed that the β-hairpin conjugated PROTAC had a greater lifetime in cells.

摘要

蛋白酶靶向嵌合体(PROTACs)已成为一类新型治疗药物,它利用泛素-蛋白酶体系统(UPS)促进“不可成药”靶点的蛋白酶体降解。基于肽的PROTACs包含三个基本成分:靶蛋白的结合基序、一种被称为降解子的能被E3连接酶识别的短氨基酸序列,以及一种细胞穿透肽以促进其被完整细胞摄取。虽然基于肽的PROTACs已被证明能成功降解众多靶点,但人们经常发现它们表现出低细胞通透性和高蛋白酶敏感性。先前的研究确定了含有β-发夹序列基序的肽,其不仅作为保护元件起作用,还作为细胞穿透肽和降解子起作用。本研究的目的是调查β-发夹序列是否可以取代常用的无结构肽序列,作为PROTAC摄取和发挥功能所需的降解子和细胞穿透肽。选择蛋白质Tau的降解作为模型系统,因为一些已发表的研究确定了一个Tau结合元件,它可以很容易地与β-发夹序列偶联。一系列时间和浓度依赖性研究证实,β-发夹序列是一种合适的替代细胞穿透肽和降解子,可促进蛋白酶体介导的Tau降解。显微镜研究证实了PROTAC的时间依赖性摄取,降解试验证实了与β-发夹偶联的PROTAC在细胞中的寿命更长。